A personalized mRNA vaccine developed by Moderna and Merck, when combined with the immunotherapy Keytruda, reduced the risk of melanoma recurrence or death by 42% compared with Keytruda alone. The results come from the Phase 3 INTerpath-001 trial, which enrolled 1,137 patients with high-risk melanoma, and were presented at the European Society for Medical Oncology (ESMO) congress held in Madrid from October 23 to 27.
- 42% reduction: The combination therapy cut the risk of recurrence or death by 42% (hazard ratio 0.58; 95% CI, 0.45-0.75; p<0.001) after a median follow-up of 24.6 months.
- Distant metastasis: The risk of distant metastasis or death fell by 38% (hazard ratio 0.62; 95% CI, 0.45-0.85).
- Two-year survival: 82.2% of patients receiving the vaccine plus Keytruda remained alive and recurrence-free at two years, versus 70.0% in the placebo group.
- Safety: Serious adverse events were similar between groups (14.2% vs. 13.4%), with no new safety signals detected.
What the Trial Actually Demonstrated
The trial measured recurrence-free survival, which counts both cancer recurrence and death as events. Overall survival data are not yet mature, and the companies describe the trend as “favorable” while the study continues. They have begun discussions with regulatory authorities, and the results have been accepted for publication in The New England Journal of Medicine.
At two years, 88.5% of patients in the vaccine group were free of distant metastasis, compared with 80.2% in the control group. The benefit appeared to emerge after the sixth month: during the first six months, the combination performed similarly to Keytruda alone (hazard ratio 0.99). From that point onward, a pre-specified sensitivity analysis showed a 58% reduction in the risk of recurrence or death and a 50% reduction in the risk of distant metastasis or death.
How a Personalized Vaccine Works
The therapy, called intismeran autogene (also known as V940 or mRNA-4157), is manufactured from each patient’s tumor sample. By comparing tumor DNA with normal DNA, researchers identify mutations unique to the cancer. This information is used to design a synthetic mRNA that encodes up to 34 neoantigens—altered proteins that the immune system can recognize as foreign.
Once injected, the body produces these proteins and trains T cells to attack cells carrying them. Keytruda (pembrolizumab) complements the vaccine by blocking the PD-1 brake that tumors use to evade the immune system. The vaccine uses the same mRNA technology platform that gained prominence with COVID-19 vaccines.
The trial enrolled patients with completely resected high-risk cutaneous melanoma (stage IIB to IV). Participants were randomized 2:1 to receive either 1 mg of the vaccine every three weeks for up to nine doses plus Keytruda every six weeks for approximately one year, or placebo plus Keytruda.
Safety Profile and Manufacturing Challenges
Severe adverse events were nearly identical between the two arms: 14.2% with the combination and 13.4% with Keytruda alone, counting grade 3 to 5 treatment-related events. Mild side effects were more common: 52.2% of patients receiving the combination experienced fever, 51% reported injection-site pain, and 38.5% had fatigue. Overall, treatment-related adverse events occurred in 95.8% of the vaccine group and 90% of the control group.
No approval date has been set. Merck and Moderna say only that they are in talks with regulators. Experts cited by New Scientist suggest some countries could approve the vaccine as early as 2027, though the timeline remains uncertain and manufacturing costs could complicate access. Each patient requires a separate tumor analysis, design, manufacturing, and quality control process—a significant industrial bottleneck.
It is important to note that this is not a preventive vaccine for the general population. It is given to patients who have already had melanoma to reduce the chance of recurrence. For primary prevention, sun protection remains the cornerstone.
Melanoma is a substantial burden: more than 338,000 cases were diagnosed worldwide in 2024, and the U.S. expects about 112,000 new cases and more than 8,500 deaths in 2026. The INTerpath program now includes nine Phase 2 and 3 trials, three of which are Phase 3 studies in non-small cell lung cancer.
This is arguably the most robust advance in adjuvant melanoma treatment since the arrival of immunotherapy, backed by a randomized, double-blind Phase 3 design and a benefit that aligns with the proposed mechanism. However, the honest headline is “fewer recurrences,” not “fewer deaths,” until overall survival data mature. The challenge that will determine its impact is not scientific but industrial: producing a unique medicine for each patient at a price health systems can afford.